EWTX logo

Edgewise Therapeutics, Inc. (EWTX) EBITDA

Annual EBITDA:

-$156.54M-$43.92M(-38.99%)
December 31, 2024

Summary

  • As of today, EWTX annual EBITDA is -$156.54 million, with the most recent change of -$43.92 million (-38.99%) on December 31, 2024.
  • During the last 3 years, EWTX annual EBITDA has fallen by -$113.60 million (-264.53%).
  • EWTX annual EBITDA is now -1497.20% below its all-time high of -$9.80 million, reached on December 31, 2019.

Performance

EWTX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXincome statement metrics

Quarterly EBITDA:

-$46.29M-$4.25M(-10.10%)
September 30, 2025

Summary

  • As of today, EWTX quarterly EBITDA is -$46.29 million, with the most recent change of -$4.25 million (-10.10%) on September 30, 2025.
  • Over the past year, EWTX quarterly EBITDA has dropped by -$6.42 million (-16.10%).
  • EWTX quarterly EBITDA is now -1342.89% below its all-time high of -$3.21 million, reached on March 31, 2020.

Performance

EWTX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXincome statement metrics

TTM EBITDA:

-$178.65M-$6.42M(-3.73%)
September 30, 2025

Summary

  • As of today, EWTX TTM EBITDA is -$178.65 million, with the most recent change of -$6.42 million (-3.73%) on September 30, 2025.
  • Over the past year, EWTX TTM EBITDA has dropped by -$33.65 million (-23.21%).
  • EWTX TTM EBITDA is now -5468.80% below its all-time high of -$3.21 million, reached on March 31, 2020.

Performance

EWTX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

EWTX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-39.0%-16.1%-23.2%
3Y3 Years-264.5%-155.8%-188.7%
5Y5 Years-1497.2%--

EWTX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-264.5%at low-155.8%at low-188.7%at low
5Y5-Year-1497.2%at low-1083.5%at low-2409.4%at low
All-TimeAll-Time-1497.2%at low-1342.9%at low-5468.8%at low

EWTX EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$46.29M(-10.1%)
-$178.65M(-3.7%)
Jun 2025
-
-$42.04M(+7.4%)
-$172.23M(-2.7%)
Mar 2025
-
-$45.41M(-1.1%)
-$167.76M(-7.1%)
Dec 2024
-$156.54M(-39.0%)
-$44.91M(-12.6%)
-$156.58M(-8.0%)
Sep 2024
-
-$39.87M(-6.1%)
-$145.00M(-8.1%)
Jun 2024
-
-$37.57M(-9.8%)
-$134.13M(-10.4%)
Mar 2024
-
-$34.23M(-2.7%)
-$121.46M(-7.8%)
Dec 2023
-$112.63M(-58.4%)
-$33.33M(-14.9%)
-$112.70M(-11.2%)
Sep 2023
-
-$29.00M(-16.5%)
-$101.36M(-12.1%)
Jun 2023
-
-$24.90M(+2.2%)
-$90.45M(-10.5%)
Mar 2023
-
-$25.46M(-15.8%)
-$81.88M(-15.1%)
DateAnnualQuarterlyTTM
Dec 2022
-$71.12M(-65.6%)
-$21.99M(-21.5%)
-$71.12M(-14.9%)
Sep 2022
-
-$18.10M(-10.8%)
-$61.88M(-9.0%)
Jun 2022
-
-$16.34M(-11.1%)
-$56.79M(-11.7%)
Mar 2022
-
-$14.70M(-15.3%)
-$50.86M(-18.4%)
Dec 2021
-$42.94M(-152.5%)
-$12.74M(+2.1%)
-$42.94M(-42.2%)
Sep 2021
-
-$13.01M(-25.0%)
-$30.20M(-75.7%)
Jun 2021
-
-$10.41M(-53.6%)
-$17.19M(-60.8%)
Mar 2021
-
-$6.78M(-73.3%)
-$10.69M(-50.1%)
Dec 2020
-$17.01M(-73.5%)
-
-
Jun 2020
-
-$3.91M(-21.9%)
-$7.12M(-121.9%)
Mar 2020
-
-$3.21M
-$3.21M
Dec 2019
-$9.80M
-
-

FAQ

  • What is Edgewise Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Edgewise Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Edgewise Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Edgewise Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of EWTX is -$156.54M

What is the all-time high annual EBITDA for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high annual EBITDA is -$9.80M

What is Edgewise Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, EWTX annual EBITDA has changed by -$43.92M (-38.99%)

What is Edgewise Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of EWTX is -$46.29M

What is the all-time high quarterly EBITDA for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high quarterly EBITDA is -$3.21M

What is Edgewise Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, EWTX quarterly EBITDA has changed by -$6.42M (-16.10%)

What is Edgewise Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of EWTX is -$178.65M

What is the all-time high TTM EBITDA for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high TTM EBITDA is -$3.21M

What is Edgewise Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, EWTX TTM EBITDA has changed by -$33.65M (-23.21%)
On this page